Literature DB >> 15490058

Long-term survival of patients with small intestinal carcinoid tumors.

Niklas Zar1, Hans Garmo, Lars Holmberg, Jonas Rastad, Per Hellman.   

Abstract

Midgut carcinoid tumors are rare and have a markedly better prognosis than adenocarcinoma in the small intestine. New diagnostic methods and medical as well as surgical therapies have evolved during the last decades, leading to more active care of these patients. Patients with small intestinal carcinoids diagnosed from 1960 to 2000 in the duodenum (n = 89) and jejunum/ileum (n = 2437) were identified in the Swedish Cancer Registry. Cases without histologic verification and autopsy cases were excluded. Overall, cause-specific and relative survival were calculated. The overall 5-, 10-, and 15 year survivals were, respectively, 60%, 46%, and 28% for duodenal tumors and 56%, 36%, and 23% for jejunal/ileal tumors. Cause-specific 5-, 10-, and 15-year survival was 94% for all three follow-up periods for duodenal tumors and 87%, 80%, and 77% for those in the jejunum/ileum. The corresponding relative survivals were, respectively, 72%, 67%, and 51% for duodenal tumors and 67%, 54%, and 44% for those in the jejunum/ileum. Sex did not influence overall or cause-specific survival. The age at diagnosis correlated inversely with overall and cause-specific survival for tumors in the jejunum/ileum. For tumors in the jejunum/ileum, the overall and cause-specific survival correlated with the time period of diagnosis, with a more favorable prognosis for those diagnosed in recent years. A multivariate Cox proportional hazards model showed similar results. We concluded that young age and diagnosis in recent years are positive predictors of survival for patients with midgut carcinoids. The divergence between cause-specific and relative survival implies the need for a more detailed analysis of the causes of death of these patients.

Entities:  

Mesh:

Year:  2004        PMID: 15490058     DOI: 10.1007/s00268-004-7610-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  33 in total

1.  Survival in small intestinal adenocarcinoma.

Authors:  N Zar; L Holmberg; E Wilander; J Rastad
Journal:  Eur J Cancer       Date:  1996-11       Impact factor: 9.162

2.  A computer program for period analysis of cancer patient survival.

Authors:  H Brenner; O Gefeller; T Hakulinen
Journal:  Eur J Cancer       Date:  2002-03       Impact factor: 9.162

3.  Diagnostic errors discovered at autopsy.

Authors:  M Britton
Journal:  Acta Med Scand       Date:  1974-09

4.  An analysis of 8305 cases of carcinoid tumors.

Authors:  I M Modlin; A Sandor
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

5.  Small bowel cancer: epidemiological and clinical characteristics from a population-based registry.

Authors:  J A DiSario; R W Burt; H Vargas; W P McWhorter
Journal:  Am J Gastroenterol       Date:  1994-05       Impact factor: 10.864

Review 6.  Chemotherapy and biotherapy in neuroendocrine tumors.

Authors:  K Oberg
Journal:  Curr Opin Oncol       Date:  1993-01       Impact factor: 3.645

7.  Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide.

Authors:  K Oberg; I Norheim; E Theodorsson
Journal:  Acta Oncol       Date:  1991       Impact factor: 4.089

Review 8.  Biology and management of the midgut carcinoid.

Authors:  M D Basson; H Ahlman; B Wangberg; I M Modlin
Journal:  Am J Surg       Date:  1993-02       Impact factor: 2.565

9.  Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.

Authors:  L Kölby; G Persson; S Franzén; B Ahrén
Journal:  Br J Surg       Date:  2003-06       Impact factor: 6.939

10.  Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide.

Authors:  B Wangberg; E Forssell-Aronsson; L E Tisell; O Nilsson; M Fjalling; H Ahlman
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

View more
  16 in total

1.  Management of gastrointestinal carcinoid tumours - 10 years experience at a district general hospital.

Authors:  Shridhar S Dronamraju; Vickram B Joypaul
Journal:  J Gastrointest Oncol       Date:  2012-06

2.  Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center.

Authors:  Olov Norlén; Peter Stålberg; Kjell Öberg; John Eriksson; Jakob Hedberg; Ola Hessman; Eva Tiensuu Janson; Per Hellman; Göran Åkerström
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

Review 3.  Early Gastroenteropancreatic Neuroendocrine Tumors: Endoscopic Therapy and Surveillance.

Authors:  Hans Scherübl; Guillaume Cadiot
Journal:  Visc Med       Date:  2017-10-10

4.  Prognostic Factors in Curative Resected Locoregional Small Intestine Neuroendocrine Neoplasms.

Authors:  Maximilian Evers; Anja Rinke; Johannes Rütz; Annette Ramaswamy; Elisabeth Maurer; Detlef K Bartsch
Journal:  World J Surg       Date:  2021-01-08       Impact factor: 3.352

5.  Management of early gastrointestinal neuroendocrine neoplasms.

Authors:  Hans Scherübl; Robert T Jensen; Guillaume Cadiot; Ulrich Stölzel; Günter Klöppel
Journal:  World J Gastrointest Endosc       Date:  2011-07-16

6.  Surgery for small-bowel neuroendocrine tumors: is there any benefit of the laparoscopic approach?

Authors:  Marleny N Figueiredo; Léon Maggiori; Sébastien Gaujoux; Anne Couvelard; Nathalie Guedj; Philippe Ruszniewski; Yves Panis
Journal:  Surg Endosc       Date:  2014-01-01       Impact factor: 4.584

7.  Early diagnosis and treatment of gastrointestinal neuroendocrine tumors.

Authors:  Hong Shen; Zhuo Yu; Jing Zhao; Xiu-Zhen Li; Wen-Sheng Pan
Journal:  Oncol Lett       Date:  2016-08-29       Impact factor: 2.967

8.  Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management.

Authors:  Hans Scherübl; Robert T Jensen; Guillaume Cadiot; Ulrich Stölzel; Günter Klöppel
Journal:  World J Gastrointest Endosc       Date:  2010-10-16

9.  Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors.

Authors:  John Eriksson; Peter Stålberg; Anders Nilsson; Johan Krause; Christina Lundberg; Britt Skogseid; Dan Granberg; Barbro Eriksson; Göran Akerström; Per Hellman
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

10.  A population-based study of outcomes in patients with gastrointestinal neuroendocrine tumours.

Authors:  Todd McMullen; Akram Al-Jahdali; Christopher de Gara; Sunita Ghosh; Alexander McEwan; Daniel Schiller
Journal:  Can J Surg       Date:  2017-06       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.